Home > Products > API > Dolutegravir
Dolutegravir
  • DolutegravirDolutegravir

Dolutegravir

Product Name:Dolutegravir
Formulae hypotheticae: C20H19F2N3O5
M. Pondus; 419.38
CAS Subcriptio Number; 1051375-16-6

Model:CAS NO:1051375-16-6

Mitte Inquisitionem

depictio producti

Dolutegravir

Product nomen:Dolutegravir 1051375-16-6
CAS No:1051375-16-6
Specification: in domo

Nomen Dolutegravir
Synonyma DolutegravirAPI;Dolutegravir(GSK1349572);2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide,N-[(2,4-difluorophenyl) methyl] 3,4,6,8,12,12a-hex ahydro-7-hydroxy-4-methyl-6,8-dioxo-,(4R,12aS)-; , 12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-Chemicus albookpyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamideDolutegravir(GSK1349572); (2,4-Difluorobenzyl) -7-h ydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1 ] oxazine-9-carboxamide;Dolutegravir,>=98%;Dolutegravirfreeacid
copyRight
M. Structure CAS # 59-02-9, Vitamin E, D-alpha-Tocopherol, (2R)-3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol
Formulae hypotheticae C20H19F2N3O5
M. Pondus 419.38
CAS Subcriptio Number 1051375-16-6


Tractantem et repono
Cautiones pro tutum pertractatio
Bene ventilatas tractantem in loco. Apta tutela vestitus. Pelle et oculis contactum fuge. Fuge formationem pulveris et aerosols. Utere instrumentis non-noctis. Ne ignis per electrostatic missionem vaporis.
Conditiones repono pro tuto, inter quaslibet incompatibilitates
Repone continens arcte clausum in loco sicco, frigido et bene ventilato. Disponunt a vasis victualibus vel materiae repugnantibus.

Imprimis usus finis (s): oeconomiae laboratoriae, ad investigationes scientificas et evolutionem tantum



Hot Tags: Dolutegravir, China, Suppliers, Fabrica, Factory
Related Categoria
Mitte Inquisitionem
Libenter placet, ut inquisitionem tuam in forma infra exhibeas. Respondebimus tibi in 24 horis.
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept